WarfarinPharmacogeneticsVitamin K Epoxide ReductasesAnticoagulantsMixed Function OxygenasesAryl Hydrocarbon HydroxylasesMicrobial ConsortiaIndividualized MedicineInternational CooperationCytochrome P-450 CYP2D6Polymorphism, GeneticGenotypeProthrombin TimeHemorrhageBiomarkers, PharmacologicalPolymorphism, Single NucleotideThromboembolismAtrial FibrillationInternational Agenciesbeta-AlanineDrug-Related Side Effects and Adverse ReactionsVitamin KDrug Dosage CalculationsGenetic VariationPharmaceutical PreparationsDrug InteractionsGenetic TestingRodenticidesTreatment OutcomeDrug TherapyCytochrome P-450 Enzyme SystemGenome-Wide Association StudyMetabolic Detoxication, DrugPharmacy ResidenciesAcenocoumarolDose-Response Relationship, DrugInternationalityStrokeRisk FactorsDihydrouracil Dehydrogenase (NADP)United StatesGenetic Predisposition to DiseaseDrug MonitoringPhenotypePlatelet Aggregation InhibitorsMethyltransferasesAspirinCohort StudiesClinical Trials as TopicVitamin K 1Cytochrome P-450 CYP3AAllelesGenome, HumanGene FrequencyInternational Normalized RatioDrug DesignRisk AssessmentPharmacokineticsBiodegradation, Environmental4-HydroxycoumarinsBlood CoagulationIntracranial HemorrhagesBenzimidazolesAzathioprineHaplotypes6-MercaptopurineAdministration, OralGlucuronosyltransferaseSleep Arousal DisordersBiotransformationNeoplasmsTranslational Medical ResearchProspective StudiesEuropeRetrospective StudiesOrganic Anion TransportersCodeineStevens-Johnson SyndromeEmbolismGenomicsDrug ResistanceThrombosisAntipsychotic Agents